Biowaiver for one strength/dose of non-linear PK [Design Issues]

posted by Tina – India, 2016-05-26 15:58 (3186 d 14:13 ago) – Posting: # 16363
Views: 2,469

Dear all,
Iam currently working on a BE study (with an anticancer drug) in cancer patients for EU submission. A higher dose is linear whilst the lower dose (in a different group of cancer patients) is non-linear. BE study with a higher dose can be planned. However, being rare condition, lower dose/strength cant be planned. Could the group members kindly help with providing a solution to waive BE study with the lower dose/strength (with non-linear pk) please? The irony is some patients in the main indication could also receive the lower dose/strength…recruitment of such patients will still be an issue. Has anyone received biowaiver for non-linear PK drug by conduct of a single study and justifying the non-conduct of the other?
Thank you for the kind help.
Kind regards,
Tina


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
79 visitors (0 registered, 79 guests [including 9 identified bots]).
Forum time: 05:12 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5